Research Article

Evaluation of Patients with Hepatic Cirrhosis due to Etiology for the Complication

Volume: 4 Number: 4 October 29, 2024
EN

Evaluation of Patients with Hepatic Cirrhosis due to Etiology for the Complication

Abstract

Objectives: Hepatic cirrhosis is a disease with high mortality. The leading causes of morbidity and mortality in patients with hepatic cirrhosis are disease-associated complications. We aimed to describe the association between the difference in laboratory parameters, complications, and commonly known causes of cirrhosis, such as hepatitis B, hepatitis C, alcoholic liver disease (NASH), and autoimmune hepatitis. Methods: We investigated 541 patients with different etiologies of cirrhosis who applied to a gastroenterology clinic from 2009 to 2018 in Florance Nightingale Hospital. All patients were divided into five groups according to the etiology of cirrhosis, such as hepatitis B, hepatitis C, alcoholic liver disease (ALD), NASH, and autoimmune hepatitis. Biochemical and metabolic parameters were evaluated between five groups. Results: 83 patients with alcoholic liver disease, 242 patients with hepatitis B-associated cirrhosis, 112 patients with hepatitis C-associated cirrhosis, 77 patients with NASH, and 27 patients with autoimmune hepatitis were enrolled. Laboratory parameters due to the etiology of hepatic cirrhosis are shown in Table 2. Ascites and hepatic encephalopathy were statistically higher in alcoholic liver disease, hepatitis B, and NASH cirrhosis, while esophageal variceal bleeding was higher in NASH and autoimmune hepatitis. Spontaneous bacterial peritonitis was statistically higher only in cirrhosis due to autoimmune hepatitis. Conclusion: It is very important to assign complications that may develop in liver cirrhosis and manage them by etiology.

Keywords

Cirrhosis, Mortality, Etiology

References

  1. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-171. doi:10.1016/j.jhep.2018.09.014
  2. Singh GK, Hoyert DL. Social epidemiology of chronic liver disease and cirrhosis mortality in the United States, 1935-1997: trends and differentials by ethnicity, socioeconomic status, and alcohol consumption. Hum Biol. 2000 Oct;72(5):801-20.
  3. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology. 2006;43(6):1303-1310. doi:10.1002/hep.21176
  4. Bayan K, Yilmaz S, Tuzun Y, Yildirim Y. Epidemiological and clinical aspects of liver cirrhosis in adult patients living in Southeastern Anatolia: leading role of HBV in 505 cases. Hepatogastroenterology. 2007;54(80):2198-2202.
  5. Waldenstrom J. Leber, Blutprotein und nahrungseiweiss, Dtsch. Gesellshaff Z € Verdan Stoffwechselkr 1950
  6. Mackay IR. Historical reflections on autoimmune hepatitis. World J Gastroenterol. 2008;14(21):3292-3300. doi:10.3748/wjg.14.3292
  7. Manns MP, Lohse AW, Vergani D. Autoimmune hepatitis--Update 2015. J Hepatol. 2015;62(1 Suppl):S100-S111. doi:10.1016/j.jhep.2015.03.005
  8. Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1(1):113-128. doi:10.1586/17474124.1.1.113
  9. McCarthy M. The "gender gap" in autoimmune disease. Lancet. 2000;356(9235):1088. doi:10.1016/S0140-6736(05)74535-9
  10. O'Shea RS, Dasarathy S, McCullough AJ; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology. 2010;51(1):307-328. doi:10.1002/hep.23258
APA
Çavuşoğlu, B., Şahin, T., & Türker, F. (2024). Evaluation of Patients with Hepatic Cirrhosis due to Etiology for the Complication. DAHUDER Medical Journal, 4(4), 83-88. https://doi.org/10.56016/dahudermj.1561401
AMA
1.Çavuşoğlu B, Şahin T, Türker F. Evaluation of Patients with Hepatic Cirrhosis due to Etiology for the Complication. DAHUDER MJ. 2024;4(4):83-88. doi:10.56016/dahudermj.1561401
Chicago
Çavuşoğlu, Betül, Tolga Şahin, and Fatih Türker. 2024. “Evaluation of Patients With Hepatic Cirrhosis Due to Etiology for the Complication”. DAHUDER Medical Journal 4 (4): 83-88. https://doi.org/10.56016/dahudermj.1561401.
EndNote
Çavuşoğlu B, Şahin T, Türker F (October 1, 2024) Evaluation of Patients with Hepatic Cirrhosis due to Etiology for the Complication. DAHUDER Medical Journal 4 4 83–88.
IEEE
[1]B. Çavuşoğlu, T. Şahin, and F. Türker, “Evaluation of Patients with Hepatic Cirrhosis due to Etiology for the Complication”, DAHUDER MJ, vol. 4, no. 4, pp. 83–88, Oct. 2024, doi: 10.56016/dahudermj.1561401.
ISNAD
Çavuşoğlu, Betül - Şahin, Tolga - Türker, Fatih. “Evaluation of Patients With Hepatic Cirrhosis Due to Etiology for the Complication”. DAHUDER Medical Journal 4/4 (October 1, 2024): 83-88. https://doi.org/10.56016/dahudermj.1561401.
JAMA
1.Çavuşoğlu B, Şahin T, Türker F. Evaluation of Patients with Hepatic Cirrhosis due to Etiology for the Complication. DAHUDER MJ. 2024;4:83–88.
MLA
Çavuşoğlu, Betül, et al. “Evaluation of Patients With Hepatic Cirrhosis Due to Etiology for the Complication”. DAHUDER Medical Journal, vol. 4, no. 4, Oct. 2024, pp. 83-88, doi:10.56016/dahudermj.1561401.
Vancouver
1.Betül Çavuşoğlu, Tolga Şahin, Fatih Türker. Evaluation of Patients with Hepatic Cirrhosis due to Etiology for the Complication. DAHUDER MJ. 2024 Oct. 1;4(4):83-8. doi:10.56016/dahudermj.1561401